Interferon-experienced patients with hepatitis C who achieved sustained virologic response with direct-acting antivirals were more likely to have a higher baseline expression of interferon-stimulated genes compared with those who experienced a virologic breakthrough, according to a recently published study.
“Our results suggest that the innate immune response may contribute to viral clearance with an interferon-free regimen,” Hawwa Alao, MD, from the National Institutes of Health in Bethesda, Md., and colleagues wrote. “We speculate that this innate immune response may prevent the emergence of resistance-associated substitutions that lead to viral breakthrough during DAA therapy.”
Alao and colleagues enrolled 13 patients with HCV genotype 1b who had previous partial or no response to pegylated interferon with ribavirin therapy. Twelve patients had the rs12979860-CT or -TT allele and twelve patients had the rs368234815-delta G genetic variant, both of which are associated with an unfavorable response to interferon treatment.